Indaptus Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Indaptus Therapeutics
INDP Stock  USD 11.60  0.29  2.56%   
Analyzing historical trends in various income statement and balance sheet accounts from Indaptus Therapeutics' financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Indaptus Therapeutics' valuation are summarized below:
Market Capitalization
6.5 M
Earnings Share
(41.44)
There are currently one hundred twenty fundamental trends for Indaptus Therapeutics that can be evaluated and compared over time across competitors. Investors and active traders are advised to confirm Indaptus Therapeutics' regular fundamental performance against the performance between 2010 and 2025 to make sure the trends are evolving in the right direction. As of 07/19/2025, Market Cap is likely to drop to about 8.6 M. In addition to that, Enterprise Value is likely to drop to about 2.4 M
Check Indaptus Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Indaptus Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 698, Other Operating Expenses of 14.7 M or Research Development of 9.6 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.9. Indaptus financial statements analysis is a perfect complement when working with Indaptus Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Indaptus Stock
Check out the analysis of Indaptus Therapeutics Correlation against competitors.
To learn how to invest in Indaptus Stock, please use our How to Invest in Indaptus Therapeutics guide.

Indaptus Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets7 M7.3 M22.1 M
Very volatile
Short and Long Term Debt Total80 K84.2 K986.6 K
Slightly volatile
Other Current Liabilities2.1 M2.1 M2.1 M
Slightly volatile
Total Current Liabilities3.4 M3.4 M3.4 M
Slightly volatile
Property Plant And Equipment Net78.1 K82.2 K3.1 M
Slightly volatile
Accounts Payable1 M870.2 K963.2 K
Slightly volatile
Cash5.5 M5.8 M14.4 M
Pretty Stable
Non Current Assets Total684.4 K720.4 K3.9 M
Pretty Stable
Cash And Short Term Investments5.5 M5.8 M17 M
Pretty Stable
Net Receivables23 K24.2 K637.6 K
Pretty Stable
Common Stock Shares Outstanding9.8 M9.4 M3.3 M
Slightly volatile
Liabilities And Stockholders Equity7 M7.3 M22.1 M
Very volatile
Other Current Assets590.6 K831.6 K604.9 K
Slightly volatile
Other Stockholder Equity90.4 M64.3 M89.4 M
Pretty Stable
Total Liabilities3.9 M3.4 M3.8 M
Pretty Stable
Total Current Assets6.3 M6.6 M18.3 M
Pretty Stable
Short Term Debt159.9 K168.3 K538.8 K
Slightly volatile
Common Stock114.1 K120.1 K404.5 K
Slightly volatile
Inventory41.4 K46.6 K50.8 K
Slightly volatile
Non Currrent Assets Other1 M638.3 K771.8 K
Pretty Stable
Property Plant Equipment70.9 K93.5 K32.7 K
Slightly volatile
Property Plant And Equipment Gross112.6 K82.2 K39.9 K
Slightly volatile
Capital Stock87.7 K120.1 K47.8 K
Slightly volatile

Indaptus Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization698735398.9 K
Slightly volatile
Other Operating Expenses14.7 M15.4 M14.5 M
Slightly volatile
Research Development9.6 M7.3 M9.6 M
Pretty Stable
Cost Of Revenue698735398.9 K
Slightly volatile
Total Operating Expenses14.2 M15.4 M14.1 M
Slightly volatile
Interest Expense710.1 K676.3 K172.7 K
Slightly volatile
Selling General Administrative5.9 M8.1 M2.7 M
Slightly volatile
Selling And Marketing Expenses86.1 K90.7 K4.7 M
Slightly volatile
Net Interest Income710.1 K676.3 K171.7 K
Slightly volatile
Interest Income710.1 K676.3 K171.7 K
Slightly volatile
Reconciled Depreciation969735972
Slightly volatile

Indaptus Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation698735398.9 K
Slightly volatile
End Period Cash Flow5.5 M5.8 M14.4 M
Pretty Stable
Begin Period Cash Flow15.2 M13.4 M14.7 M
Slightly volatile
Net Borrowings777.2 K1.3 M579.2 K
Slightly volatile
Stock Based Compensation1.8 M2.3 M809.8 K
Slightly volatile
Change To Netincome3.4 M3.2 M949.7 K
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Average Payables644.5 K754.3 K462.2 K
Slightly volatile
Capex To Depreciation91.5687.225.5805
Slightly volatile
Inventory Turnover5.265.926.4555
Slightly volatile
Days Of Inventory On Hand44.3849.9354.4379
Slightly volatile
Payables Turnover0.00140.00142.6654
Very volatile
Average Inventory20.7 K23.3 K25.4 K
Slightly volatile
Cash Per Share0.590.618553.2348
Pretty Stable
Days Payables Outstanding216.5 K206.2 K104.2 K
Slightly volatile
Income Quality0.690.82030.8589
Pretty Stable
Current Ratio1.851.95016.2536
Pretty Stable
Capex Per Share0.01790.01884.3262
Very volatile
Average Receivables502.3 K640.1 K683.3 K
Pretty Stable
Interest Debt Per Share0.00850.0090.5205
Slightly volatile
Debt To Assets0.01090.01150.1234
Slightly volatile
Operating Cycle44.3849.9354.4379
Slightly volatile
Days Of Payables Outstanding216.5 K206.2 K104.2 K
Slightly volatile
Ebt Per Ebit0.790.97760.9796
Pretty Stable
Total Debt To Capitalization0.01980.02090.2817
Slightly volatile
Quick Ratio1.851.95016.251
Pretty Stable
Net Income Per E B T1.091.11.0078
Slightly volatile
Cash Ratio1.621.70514.4581
Very volatile
Days Of Inventory Outstanding44.3849.9354.4379
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.251.171.1344
Pretty Stable
Debt Ratio0.01090.01150.1234
Slightly volatile

Indaptus Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap8.6 M9.1 M64.4 M
Pretty Stable

Indaptus Fundamental Market Drivers

Cash And Short Term Investments5.8 M

Indaptus Upcoming Events

15th of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
15th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Indaptus Therapeutics Financial Statements

Indaptus Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Indaptus Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Indaptus Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Indaptus Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Cost Of Revenue 735.00  698.25 

Additional Tools for Indaptus Stock Analysis

When running Indaptus Therapeutics' price analysis, check to measure Indaptus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Indaptus Therapeutics is operating at the current time. Most of Indaptus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Indaptus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Indaptus Therapeutics' price. Additionally, you may evaluate how the addition of Indaptus Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY